AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39557109
Drug: Apixaban +
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban + aspirin
Trial: 39557109
Drug: Warfarin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin + aspirin
Trial: 39557109
Drug: Apixaban vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban vs. Warfarin
Trial: 39557109
Drug: Aspirin vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin vs. Placebo
Trial: 39557487
Drug: Fezolinetant 45
RxNorm normalized name: fezolinetant 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fezolinetant 45 mg once daily for 24 weeks
Trial: 39557549
Drug: mHealth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth treatment (audio-only mobile phone)
Trial: 39557557
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of acetylsalicylic acid daily (LDA)
Trial: 39557997
Drug: Daily circadian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily circadian phase shifts
Trial: 39558280
Drug: Group Antenatal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Antenatal Care (G-ANC)
Trial: 39558302
Drug: Daily assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily assessments via the patientMpower app including handheld spirometry and exercise tests.
Trial: 39558601
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of analgesics
Trial: 39560075
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (high-dose greater than 1000 mg/day)
Trial: 39560398
Drug: CIH therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIH therapies (n = 140)
Trial: 39560548
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of PG201 (405.4 mg) and celecoxib (100 mg)
Trial: 39560548
Drug: Individual formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual formulations of PG201 and celecoxib
Trial: 39560548
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of PG201 and celecoxib
Trial: 39560548
Drug: Both FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both FDC and individual formulations
Trial: 39560771
Drug: Prophylactic dose
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dose of enoxaparin starting at 0.5 mg/kg adjusted to anti-Xa range of 0.2-0.5 IU/mL for older children
Trial: 39560771
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of enoxaparin starting at 1.5 mg/kg adjusted to anti-Xa range of greater than 0.5-1.0 IU/mL or 0.2-0.5 IU/mL for infants
Trial: 39560862
Drug: Adavosertib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (150 mg bid for 3 days on/4 days off) plus Durvalumab (1500 mg Q4W)
Trial: 39560862
Drug: Adavosertib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (300 mg qd for 5 days on/2 days off) plus Durvalumab (1500 mg Q4W)
Trial: 39561184
Drug: Single-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose albendazole (ALB)
Trial: 39561225
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg biweekly in addition to high-intensity statins
Trial: 39561281
Drug: dVHH NS7CAR-T
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dVHH NS7CAR-T cells (dosage levels: 5×10^5/kg and 1×10^6/kg)
Trial: 39561384
Drug: UGN-101 (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-101 (mitomycin reverse thermal gel)
Trial: 39561689
Drug: PS-enriched soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS-enriched soy milk (2 g/day)
Trial: 39563311
Drug: Home-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based rehabilitation exercise using elastic bands (performed exercise dose measured in repetitions/week)
Trial: 39563457
Drug: Comparator (rabies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (rabies vaccine)
Trial: 39563465
Drug: FC-FORT intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FC-FORT intervention (7 consecutive weeks of virtual group therapy and homework)
Trial: 39565030
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of antibiotic treatment (per-protocol analysis)
Trial: 39565030
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of antibiotic treatment (per-protocol analysis)
Trial: 39565228
Drug: Secukinumab (SEC)
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab (SEC) 300 mg s.c. administered regularly until week 16, followed by randomization to SEC or placebo up to week 32.
Trial: 39565228
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after SEC treatment.
Trial: 39565228
Drug: Secukinumab (SEC)
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab (SEC) treatment.
Trial: 39565449
Drug: Lactoferrin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin (100 mg/day for 4 weeks or until discharge)
Trial: 39565495
Drug: Vepdegestrant 200
RxNorm normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vepdegestrant 200 mg once daily (QD)
Trial: 39565495
Drug: Vepdegestrant 200
RxNorm normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vepdegestrant 200 mg QD
Trial: 39565570
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pembrolizumab plus radium-223
Trial: 39565703
Drug: Mandala coloring
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandala coloring for a minimum of 30 minutes during and after chemotherapy treatment.
Trial: 39565908
Drug: Grade 1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 1-2 treatment-related irAEs
Trial: 39565908
Drug: Grade 3-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 3-4 treatment-related irAEs
Trial: 39565980
Drug: Middle meningeal
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle meningeal artery embolization (adjunct to standard treatment)
Trial: 39566128
Drug: Promestriene treatment
RxNorm normalized name: promestriene
DrugBank: Promestriene (DB12487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promestriene treatment (Control)
Trial: 39566464
Drug: Durvalumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab with chemotherapy
Trial: 39566600
Drug: Low-carbohydrate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate diet (LCD) - 75 g carbohydrates for 8 weeks
Trial: 39566600
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet (LED) - 180 g carbohydrates for 8 weeks
Trial: 39567210
Drug: IO-108 monotherapy
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO-108 monotherapy
Trial: 39567210
Drug: IO-108 monotherapy
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO-108 monotherapy and combination therapy
Trial: 39567211
Drug: Nemvaleukin alfa
RxNorm normalized name: Nemvaleukin alfa
DrugBank: Nemvaleukin alfa (DB18187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemvaleukin alfa monotherapy (6 µg/kg/day)
Trial: 39567211
Drug: Nemvaleukin alfa
RxNorm normalized name: Nemvaleukin alfa
DrugBank: Nemvaleukin alfa (DB18187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemvaleukin alfa (dose-escalation)
Trial: 39568009
Drug: Modified Kasai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Kasai operation combined with autologous bone marrow mononuclear cell (BMMNC) infusion
Trial: 39568724
Drug: 18 g sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g sunflower lecithin (LPL)
Trial: 39568724
Drug: 15 g oat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g oat polar lipids (OPL)
Trial: 39568724
Drug: 18 g rapeseed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g rapeseed oil (RSO)
Trial: 39568790
Drug: Self-administered intravaginal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intravaginal 5% 5-Fluorouracil (5FU) cream
Trial: 39569450
Drug: Stool energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stool energy content at discharge (AN-DIS: 5.72 ± 0.86 kcal/g)
Trial: 39569542
Drug: Patient-administered audio
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-administered audio recordings
Trial: 39570031
Drug: S315 (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S315 (480 mg, 960 mg, 1920 mg, 3840 mg, 7680 mg)
Trial: 39570031
Drug: S315 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S315 (various doses)
Trial: 39570078
Drug: Anticoagulant
RxNorm normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulant
Trial: 39570620
Drug: Olverembatinib 30
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olverembatinib 30 mg every other day
Trial: 39570620
Drug: Olverembatinib 40
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olverembatinib 40 mg every other day
Trial: 39570620
Drug: Olverembatinib 50
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olverembatinib 50 mg every other day
Trial: 39570620
Drug: Prior ponatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior ponatinib treatment
Trial: 39570708
Drug: 177Lu-Dotatate treatment
RxNorm normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177Lu-Dotatate treatment
Trial: 39570708
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy (everolimus [Afinitor] and sunitinib [Sutent])
Trial: 39570992
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (oCEE) - Premarin, 0.45 mg/d
Trial: 39570992
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (tE2) - Climara, 50 μg/d
Trial: 39571342
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (200 mL daily, ∼600 mg nitrate)
Trial: 39571342
Drug: Placebo (∼60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (∼60 mg nitrate)
Trial: 39571596
Drug: Short-course hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course hypofractionated proton beam therapy
Trial: 39571744
Drug: AbobotulinumtoxinA (AboBoNT-A)
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA (AboBoNT-A) injections
Trial: 39571744
Drug: AbobotulinumtoxinA (AboBoNT-A)
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA (AboBoNT-A) injections with guidance technique
Trial: 39572389
Drug: Combined CRMRF
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CRMRF and PNF treatment
Trial: 39572395
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 mg once daily) in combination with bendamustine and rituximab (IBR) for six 28-day cycles
Trial: 39572739
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) group, 250 µg injected into the silicone oil after surgery and at weeks 3 and 6 postoperatively.
Trial: 39572979
Drug: Nivolumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until disease progression or unacceptable toxicity
Trial: 39572979
Drug: Nivolumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Trial: 39574186
Drug: Prochlorperazine maleate
RxNorm normalized name: Prochlorperazine Maleate
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prochlorperazine maleate (oral, three times daily for 24 hours)
Trial: 39574186
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, three times daily for 24 hours)
Trial: 39574220
Drug: MBX 2109
RxNorm normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX 2109 (200, 400, 600, and 900 μg)
Trial: 39574348
Drug: Brensocatib (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib (single oral dose)
Trial: 39574508
Drug: IVIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 10% administered at various dosing regimens (0.4-2 g/kg once every 1-4 weeks)
Trial: 39574508
Drug: IVIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 10% with dose splitting over multiple days
Trial: 39574508
Drug: IVIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 10% with dosing intervals more frequent than Q4W
Trial: 39575028
Drug: Neoadjuvant anti-PD-L1
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant anti-PD-L1 (Durvalumab) and anti-CTLA-4 (Tremelimumab) for three cycles of four weeks/cycle along with external beam radiation for five weeks, followed by wide surgical resection and adjuvant Durvalumab monotherapy for four cycles.
Trial: 39575188
Drug: Fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160 mg once daily along with 1 g of mesalamine three times daily
Trial: 39575188
Drug: Placebo along
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo along with 1 g of mesalamine three times daily
Trial: 39575565
Drug: EMB-09 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMB-09 (a novel Fc-silenced tetravalent PD-L1/OX40 bispecific antibody)
Trial: 39575728
Drug: Unconditional Cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS)
Trial: 39575728
Drug: Unconditional Cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS) + Social and Behaviour Change Communication (SBCC)
Trial: 39575944
Drug: nPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nPAP therapy (BiPAP, APAP, CPAP, ASV)
Trial: 39575944
Drug: nPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nPAP therapy
Trial: 39576286
Drug: CT (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (conventional therapy)
Trial: 39576637
Drug: Intervention clinics
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention clinics with nurse care management for OUD treatment
Trial: 39576962
Drug: Itacitinib 200
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib 200 mg daily from day -3 through +100 or +180, followed by a taper
Trial: 39576962
Drug: Itacitinib 200
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib 200 mg daily
Trial: 39577214
Drug: IV calcium
RxNorm normalized name: Viactiv Calcium Plus D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV calcium chloride 90 mg (C90D)
Trial: 39577214
Drug: IV calcium
RxNorm normalized name: Viactiv Calcium Plus D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV calcium chloride 180 mg (C180D)
Trial: 39577214
Drug: IV calcium
RxNorm normalized name: Viactiv Calcium Plus D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV calcium pretreatment (both doses)
Trial: 39577511
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dd-cfDNA and NTproBNP
Trial: 39577511
Drug: Cut-off point
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cut-off point of 0.10% for dd-cfDNA and 1,000 UI/ml for NTproBNP
Trial: 39577708
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (300,000 IU bolus followed by 1400 IU daily for 150 days)
Trial: 39577828
Drug: Pred Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pred Low (5 mg/d, every other week × 6 months)
Trial: 39577828
Drug: Pred High
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pred High (20 mg prednisone taper, every other month × 3 months)
Trial: 39577828
Drug: Pred PRN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pred PRN (20 mg prednisone taper × 3 courses maximum if sperm counts were declining or 0)
Trial: 39577920
Drug: Early-start group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-start group (100 mg acetylsalicylic acid starting on the third day after surgery until the 90th day)
Trial: 39577920
Drug: Late-start group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-start group (100 mg acetylsalicylic acid starting on the 30th day after surgery until the 90th day)
Trial: 39577921
Drug: Intravenous glibenclamide
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glibenclamide (8·6 mg over 72 h)
Trial: 39577975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Sputum-Xpert Ultra with AlereLAM
Trial: 39577975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Sputum-Xpert Ultra with Urine-Xpert Ultra
Trial: 39577975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three tests (Sputum-Xpert Ultra, AlereLAM, Urine-Xpert Ultra)
Trial: 39578038
Drug: DOR/DTG/3TC (co-formulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOR/DTG/3TC (co-formulated doravirine, dolutegravir, and lamivudine) once daily
Trial: 39578265
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal cannula (HFNC) at 50 to 60 L.min
Trial: 39578347
Drug: GN-037 cream
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GN-037 cream
Trial: 39578347
Drug: Clobetasol 17-propionate
RxNorm normalized name: clobetasol 17-propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol 17-propionate (CP) cream
Trial: 39578347
Drug: Vehicle (V)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (V) cream
Trial: 39578921
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical sirolimus applied to the face for 24 weeks
Trial: 39578921
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical sirolimus
Trial: 39580145
Drug: Faricimab 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab 6.0 mg every 8 weeks (Q8W)
Trial: 39580145
Drug: Faricimab 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab 6.0 mg according to a personalized treat-and-extend (T&E)-based regimen
Trial: 39580145
Drug: Aflibercept 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2.0 mg every 8 weeks (Q8W)